Skip to main content
Premium Trial:

Request an Annual Quote

LifeCodexx, Elucigene Diagnostics Partner to Offer NIPT in UK and Ireland

NEW YORK (GenomeWeb) – LifeCodexx and Elucigene Diagnostics said today that they have partnered to make LifeCodexx's noninvasive prenatal screening test, PrenaTest, available to patients in the UK and Ireland.

Konstanz, Germany based-LifeCodexx launched PrenaTest based on technology it licensed from Sequenom in 2012 and has made the test available throughout Europe. Elucigene Diagnostics, based in Manchester, UK, is a developer and distributor of prenatal and human genetic diagnostics.

Mark Street-Docherty, commercial manager of Elucigene Diagnostics, said in a statement that offering LifeCodexx's PrenaTest "complements our continued support for prenatal testing accuracy."

PrenaTest is now available in more than 40 countries throughout Europe and the Middle East, Michael Lutz, CEO of LifeCodexx, noted in a statement.

Earlier this year, LifeCodexx inked deals with partner labs in Germany and Switzerland for the test.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.